Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amarin Corporation PLC stock logo
AMRN
Amarin
$11.31
-0.6%
$12.53
$11.25
▼
$17.31
$238.34M0.8175,981 shs81,786 shs
Ocugen, Inc. stock logo
OCGN
Ocugen
$0.77
-6.6%
$0.94
$0.69
▼
$2.73
$262.28M2.047.23 million shs9.03 million shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amarin Corporation PLC stock logo
AMRN
Amarin
0.00%-1.98%+0.53%-18.77%-30.35%
Ocugen, Inc. stock logo
OCGN
Ocugen
0.00%-10.51%+6.09%-39.80%-30.44%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amarin Corporation PLC stock logo
AMRN
Amarin
$11.31
-0.6%
$12.53
$11.25
▼
$17.31
$238.34M0.8175,981 shs81,786 shs
Ocugen, Inc. stock logo
OCGN
Ocugen
$0.77
-6.6%
$0.94
$0.69
▼
$2.73
$262.28M2.047.23 million shs9.03 million shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amarin Corporation PLC stock logo
AMRN
Amarin
0.00%-1.98%+0.53%-18.77%-30.35%
Ocugen, Inc. stock logo
OCGN
Ocugen
0.00%-10.51%+6.09%-39.80%-30.44%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amarin Corporation PLC stock logo
AMRN
Amarin
1.33
Sell$13.0014.94% Upside
Ocugen, Inc. stock logo
OCGN
Ocugen
2.60
Moderate Buy$9.501,128.98% Upside

Current Analyst Ratings Breakdown

Latest OCGN and AMRN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/4/2026
Ocugen, Inc. stock logo
OCGN
Ocugen
Reiterated RatingSell (D-)
11/3/2026
Amarin Corporation PLC stock logo
AMRN
Amarin
DowngradeStrong-Buy ➝ Hold
10/15/2026
Amarin Corporation PLC stock logo
AMRN
Amarin
Reiterated RatingSell (D-)
10/5/2026
Amarin Corporation PLC stock logo
AMRN
Amarin
UpgradeHold ➝ Strong-Buy
8/21/2026
Amarin Corporation PLC stock logo
AMRN
Amarin
Initiated CoverageUnderweight$13.00
8/17/2026
Amarin Corporation PLC stock logo
AMRN
Amarin
DowngradeStrong-Buy ➝ Hold
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amarin Corporation PLC stock logo
AMRN
Amarin
$176.11M1.35$0.36 per share31.53$22.07 per share0.51
Ocugen, Inc. stock logo
OCGN
Ocugen
$4.78M54.87N/AN/A($0.04) per share-19.33
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amarin Corporation PLC stock logo
AMRN
Amarin
-$38.80M-$0.96N/AN/AN/A-10.87%-0.52%-0.36%N/A
Ocugen, Inc. stock logo
OCGN
Ocugen
-$67.85M-$0.20N/AN/AN/AN/A-127,987.80%-98.50%N/A

Latest OCGN and AMRN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/28/2026Q3 2026
Amarin Corporation PLC stock logo
AMRN
Amarin
-$0.0972$0.01+$0.1072$0.01$43.76 million$39.55 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amarin Corporation PLC stock logo
AMRN
Amarin
N/AN/AN/AN/AN/A
Ocugen, Inc. stock logo
OCGN
Ocugen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amarin Corporation PLC stock logo
AMRN
Amarin
N/A
3.50
2.59
Ocugen, Inc. stock logo
OCGN
Ocugen
4.17
0.77
0.77

Institutional Ownership

CompanyInstitutional Ownership
Amarin Corporation PLC stock logo
AMRN
Amarin
22.25%
Ocugen, Inc. stock logo
OCGN
Ocugen
10.27%

Insider Ownership

CompanyInsider Ownership
Amarin Corporation PLC stock logo
AMRN
Amarin
4.21%
Ocugen, Inc. stock logo
OCGN
Ocugen
3.95%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amarin Corporation PLC stock logo
AMRN
Amarin
8021.07 million20.19 millionOptionable
Ocugen, Inc. stock logo
OCGN
Ocugen
116339.31 million325.90 millionOptionable

Recent News About These Companies

Ocugen Stock Gets Stronger EPS Forecast from Noble Financial
Research Analysts Issue Forecasts for Ocugen FY2026 Earnings
H.C. Wainwright Remains a Buy on Ocugen (OCGN)
HC Wainwright Issues Optimistic Estimate for Ocugen Earnings
Ocugen (NASDAQ:OCGN) Raised to "Hold" at Wall Street Zen
Wall Street Zen Upgrades Ocugen (NASDAQ:OCGN) to "Hold"
Ocugen, Inc. (OCGN) Q3 2026 Earnings Call Transcript
Ocugen (OCGN) Q3 2026 Earnings
Ocugen (OCGN) Reports Q3 Loss, Tops Revenue Estimates
Ocugen (OCGN) Q3 2026 Earnings Call Transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amarin stock logo

Amarin NASDAQ:AMRN

$11.31 -0.07 (-0.62%)
Closing price 04:00 PM Eastern
Extended Trading
$11.31 0.00 (0.00%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Ocugen stock logo

Ocugen NASDAQ:OCGN

$0.77 -0.05 (-6.62%)
Closing price 04:00 PM Eastern
Extended Trading
$0.78 +0.00 (+0.26%)
As of 04:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.